Arkolith/Insider Trading/TOVX/Form 4

Shallcross Steven A

CEO and CFO, DirectorTheriva Biologics, Inc. (TOVX) · full profile →Form 4 · filed Jan 3, 2023
Net Buying
Open-Market Buys
$44K
Open-Market Sells
$0
Net Open-Market Flow
$44K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 29, 2022Buy(P)100K$0.44$44K110K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-000023) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML